El Paso, Texas, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTC-BB: "BIEI") announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder.
Dr. Vigerust, MS, PhD is a former Research Assistant Professor of Pathology at Vanderbilt University Medical School and a former Health Research Scientist with the US Department of Veterans Affairs. His research focuses on mechanisms of virus-innate immune response and the pathogenesis of inflammation in tumorigenesis and neurodegeneration. Recent research interests revolve around traumatic brain injury and molecules of the innate immune system. Dr Vigerust received a Bachelors Degree in Biology and Chemistry from the University of Texas at El Paso, a Masters in Microbiology and Immunology from Texas Tech University and a PhD in Cellular and Molecular Pathology from Vanderbilt University and conducted postdoctoral work in Infectious Disease at St. Jude Children's Research Hospital, followed by a second fellowship at Vanderbilt Medical School in Pediatric Infectious Disease. Dr.Vigerust has published in international journals, is an active editor and reviewer for several journals and was the recipient of several awards for his research over the past 12 years.
William A. Hartman, President & CEO of Premier Biomedical stated, "We are pleased to strengthen our technical staff with the impressive credentials possessed by Dr Vigerust. We will immediately utilize his experience and knowledge to expedite the advancement of our R&D programs on traumatic brain injury, breast cancer, Alzheimer's disease and MS with our partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). We are anticipating several more additions to our Scientific Advisory Board in the very near future."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
CONTACT: William A. Hartman President/CEO Premier Biomedical, Inc. email@example.com 814-786-8849 or 724-372-5242
Source:Premier Biomedical, Inc.